Key result
Early cardiac sarcoidosis is linked to ~31% greater complete response to immunosuppression versus late-stage disease.
Why the study?
Does the utility of 18F-FDG PET/CT and CMR differ in early versus late cardiac sarcoidosis for assessing response to immunosuppressive therapy?
Observational
Does the utility of 18F-FDG PET/CT and CMR differ in early versus late cardiac sarcoidosis for assessing response to immunosuppressive therapy?
Absolute Event Rate: 62.5% vs 47.8%
p-value: p=0.019
18F-FDG PET/CT appears more sensitive and useful than CMR for diagnosing and assessing response to immunosuppressive therapy in early cardiac sarcoidosis.
Supports earlier immunosuppressive therapy initiation in cardiac sarcoidosis; leaves open optimal PET/CT versus CMR use for staging and monitoring.
BACKGROUND AND AIMS: F-FDG-PET/CT) and cardiac magnetic resonance imaging(CMR) in patients with early- and late-stage CS. METHODS: F-FDG0PET/CT and CMR within 2 weeks of initial clinical presentation. Patients were divided into early-(<6 months) and late-stage groups based on the time since their first cardiac presentation. Myocardial uptake and late gadolinium enhancement(LGE) were qualitatively and quantitatively assessed. Complete clinical, echocardiographic, and radiological responses were assessed after 4-6 months of immunosuppressive therapy(IST). RESULTS: and more extensive LV involvement than those with late CS. Complete response to IST was more common in patients with early CS than in those with late CS(62.5 %vs.47.8 %,p = 0.019). In the early CS cohort, patients without LGE had a higher rate of complete response following IST than those with LGE (86.7 %vs.53.7 %,p = 0.025). CONCLUSION: F-FDG-PET/CT appears to be more sensitive and useful than CMR for diagnosis and assessment of response to IST.
No takes yet. Share an insight, caveat, or question.
Subramanian et al. (2025) conducted an observational in Cardiac Sarcoidosis. 18F-FDG-PET/CT and CMR vs. Early vs. Late stage was evaluated on Complete clinical, echocardiographic, and radiological responses after 4-6 months of immunosuppressive therapy (p=0.019). Complete response to immunosuppressive therapy was significantly higher in patients with early cardiac sarcoidosis compared to late-stage disease (62.5% vs. 47.8%, p=0.019).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: